• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Are some children with empyema at risk for treatment failure with fibrinolytics? A multicenter cohort study.

作者信息

Livingston Michael H, Cohen Eyal, Giglia Lucy, Pirrello David, Mistry Niraj, Mahant Sanjay, Weinstein Michael, Connolly Bairbre, Himidan Sharifa, Bütter Andreana, Walton J Mark

机构信息

McMaster Pediatric Surgery Research Collaborative, McMaster University, Hamilton, Ontario, Canada; Clinician Investigator Program, McMaster University, Hamilton, Ontario, Canada.

Division of Pediatric Medicine, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.

出版信息

J Pediatr Surg. 2016 May;51(5):832-7. doi: 10.1016/j.jpedsurg.2016.02.032. Epub 2016 Feb 13.

DOI:10.1016/j.jpedsurg.2016.02.032
PMID:26964704
Abstract

BACKGROUND

Guidelines recommend that children with empyema be treated initially with chest tube insertion and intrapleural fibrinolytics. Some patients have poor outcomes with this approach, and it is unclear which factors are associated with treatment failure.

METHODS

Possible risk factors were identified through a review of the literature. Treatment failure was defined as need for repeat pleural drainage and/or total length of stay greater than 2weeks.

RESULTS

We retrospectively identified 314 children with empyema treated with fibrinolytics at The Hospital for Sick Children (2000-2013, n=195), Children's Hospital, London Health Sciences Centre (2009-2013, n=39), and McMaster Children's Hospital (2007-2014, n=80). Median length of stay was 11days (range 5-69days). Thirteen percent of children required repeat drainage procedures, and 34% experienced treatment failure. There were no deaths. White blood cell count, erythrocyte sedimentation rate, C-reactive protein, albumin, urea to creatinine ratio, and signs of necrosis on initial chest x-ray were not associated with treatment failure. Multivariable logistic regression demonstrated increased risk with positive blood culture (odds ratio=2.7), immediate admission to intensive care (odds ratio=2.6), and absence of complex septations on baseline ultrasound (odds ratio=2.1). Male gender and platelet count were associated with treatment failure in the univariate analysis but not in the multivariable model.

CONCLUSIONS

Predicting which children with empyema are at risk for treatment failure with fibrinolytics remains challenging. Risk factors include positive blood culture, immediate admission to intensive care, and absence of complex septations on ultrasound. Routine blood work and inflammatory markers have little prognostic value.

摘要

相似文献

1
Are some children with empyema at risk for treatment failure with fibrinolytics? A multicenter cohort study.
J Pediatr Surg. 2016 May;51(5):832-7. doi: 10.1016/j.jpedsurg.2016.02.032. Epub 2016 Feb 13.
2
Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema: A Randomized Clinical Trial.胸腔内组织型纤溶酶原激活剂和脱氧核糖核酸酶α联合治疗与单独使用组织型纤溶酶原激活剂治疗儿童脓胸的疗效:一项随机临床试验。
JAMA Pediatr. 2020 Apr 1;174(4):332-340. doi: 10.1001/jamapediatrics.2019.5863.
3
Intrapleural Dornase and Tissue Plasminogen Activator in pediatric empyema (DTPA): a study protocol for a randomized controlled trial.小儿脓胸的胸膜腔内使用 Dornase 和组织型纤溶酶原激活剂(DTPA):一项随机对照试验的研究方案
Trials. 2017 Jun 24;18(1):293. doi: 10.1186/s13063-017-2026-0.
4
Drainage, fibrinolytics, or surgery: a comparison of treatment options in pediatric empyema.引流、纤维蛋白溶解剂或手术:小儿脓胸治疗方案的比较
J Pediatr Surg. 2004 Nov;39(11):1638-42. doi: 10.1016/j.jpedsurg.2004.07.015.
5
Reduction in the need for surgery and mortality after early administration of fibrinolytics following empyema drainage.在脓胸引流后早期给予纤溶药物可减少手术需求和死亡率。
Eur J Cardiothorac Surg. 2024 Jul 1;66(1). doi: 10.1093/ejcts/ezae263.
6
Impact of fibrinolytics on the outcome of empyema in South African children.
S Afr Med J. 2015 Sep 21;105(7):549-53. doi: 10.7196/SAMJnew.7796.
7
Cost-effectiveness of competing strategies for the treatment of pediatric empyema.小儿脓胸治疗竞争策略的成本效益
Pediatrics. 2008 May;121(5):e1250-7. doi: 10.1542/peds.2007-1886.
8
A retrospective study to evaluate the safety and efficacy of intrapleural alteplase in pediatric empyema.回顾性研究评估胸腔内注射阿替普酶治疗小儿脓胸的安全性和有效性。
Przegl Epidemiol. 2024 Sep 18;78(2):145-149. doi: 10.32394/pe/189711. Epub 2024 Jun 7.
9
Seventeen-year study shows rise in parapneumonic effusion and empyema with higher treatment failure after chest tube drainage.一项为期 17 年的研究表明,在接受胸腔引流管治疗后,类肺炎性胸腔积液和脓胸的发生率增加,且治疗失败率更高。
Acta Paediatr. 2014 Jan;103(1):93-9. doi: 10.1111/apa.12426. Epub 2013 Nov 11.
10
Making the transition from video-assisted thoracoscopic surgery to chest tube with fibrinolytics for empyema in children: Any change in outcomes?儿童脓胸从电视辅助胸腔镜手术过渡到使用纤维蛋白溶解剂的胸管引流:结局有任何变化吗?
Can J Surg. 2016 Jun;59(3):167-71. doi: 10.1503/cjs.014714.

引用本文的文献

1
A Comprehensive Review of Pediatric Necrotizing Pneumonia.小儿坏死性肺炎综合综述
Children (Basel). 2025 Sep 17;12(9):1248. doi: 10.3390/children12091248.
2
Use of Intrapleural Alteplase in the Treatment of Parapneumonic Effusion in Children: A Report of a 10-year Experience.胸膜腔内使用阿替普酶治疗儿童类肺炎性胸腔积液:一项10年经验报告
J Pediatr Pharmacol Ther. 2025 Aug;30(4):484-493. doi: 10.5863/JPPT-24-00057. Epub 2025 Aug 11.
3
Narrative review and creation of an institutional protocol for the use of fibrinolytics in parapneumonic effusion in children.
关于儿童肺炎旁胸腔积液中使用纤溶药物的叙述性综述及机构方案制定
J Pediatr (Rio J). 2025 May-Jun;101(3):324-331. doi: 10.1016/j.jped.2025.01.005. Epub 2025 Mar 11.
4
Contemporary use of fibrinolytics in the management of pediatric empyema.当代在小儿脓胸管理中纤溶药物的应用。
Pediatr Surg Int. 2024 Nov 4;40(1):289. doi: 10.1007/s00383-024-05868-w.
5
From Bedside to the Bench-A Call for Novel Approaches to Prognostic Evaluation and Treatment of Empyema.从床边到实验室——呼吁采用新方法进行脓胸的预后评估和治疗
Front Pharmacol. 2022 Jan 20;12:806393. doi: 10.3389/fphar.2021.806393. eCollection 2021.
6
Population-Based Cohort of Children With Parapneumonic Effusion and Empyema Managed With Low Rates of Pleural Drainage.基于人群的胸腔积液和脓胸儿童队列,采用低胸腔引流率进行管理。
Front Pediatr. 2021 Jul 21;9:621943. doi: 10.3389/fped.2021.621943. eCollection 2021.
7
Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema: A Randomized Clinical Trial.胸腔内组织型纤溶酶原激活剂和脱氧核糖核酸酶α联合治疗与单独使用组织型纤溶酶原激活剂治疗儿童脓胸的疗效:一项随机临床试验。
JAMA Pediatr. 2020 Apr 1;174(4):332-340. doi: 10.1001/jamapediatrics.2019.5863.
8
Surgical and nonsurgical outcomes for treating a cohort of empyema thoracis patients: A monocenteric retrospective cohort study.治疗一组脓胸患者的手术和非手术结果:一项单中心回顾性队列研究。
Ann Med Surg (Lond). 2017 Oct 13;24:19-24. doi: 10.1016/j.amsu.2017.10.002. eCollection 2017 Dec.
9
Intrapleural Dornase and Tissue Plasminogen Activator in pediatric empyema (DTPA): a study protocol for a randomized controlled trial.小儿脓胸的胸膜腔内使用 Dornase 和组织型纤溶酶原激活剂(DTPA):一项随机对照试验的研究方案
Trials. 2017 Jun 24;18(1):293. doi: 10.1186/s13063-017-2026-0.